Is PAVMZ or ORCC a better dividend investment in 2026?

PAVMZ currently yields 222222.22% with a 5% 5-year dividend growth rate. ORCC yields 9.79% with 5% growth. The better choice depends on your goal: PAVMZ offers higher current income.

What is the dividend yield difference between PAVMZ and ORCC?

PAVMZ has a forward dividend yield of 222222.22% ($2.00/share annually). ORCC yields 9.79% ($1.32/share annually). The yield gap is 222212.43 percentage points.

Home › Compare › PAVMZ vs ORCC

PAVMZ vs ORCC: Dividend Comparison 2026

PAVMZ yields 222222.22% · ORCC yields 9.79%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 PAVMZ wins by $1.4076447531278624e+30M in total portfolio value

INVESTMENT

TIME HORIZON10 years

PAVMZ

● Live price

222222.22%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$1.4076447531278624e+30M

Annual income

$1,406,399,782,569,334,400,000,000,000,000,000,000.00

Full PAVMZ calculator →

ORCC

● Live price

9.79%

Share price

$13.48

Annual div

$1.32

5Y div CAGR

-50%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$21.4K

Annual income

$1.04

Full ORCC calculator →

Portfolio growth — PAVMZ vs ORCC

📍 PAVMZ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	PAVMZ	ORCC
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, PAVMZ + ORCC cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

PAVMZ pays

ORCC pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PAVMZ

Annual income on $10K today (after 15% tax)

$18,888,888.89/yr

After 10yr DRIP, annual income (after tax)

$1,195,439,815,183,934,200,000,000,000,000,000,000.00/yr

ORCC

Annual income on $10K today (after 15% tax)

$832.34/yr

After 10yr DRIP, annual income (after tax)

$0.88/yr

At 15% tax rate, PAVMZ beats the other by $1,195,439,815,183,934,200,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PAVMZ + ORCC for your $10,000?

PAVMZ: 50%ORCC: 50%

100% ORCC50/50100% PAVMZ

Portfolio after 10yr

$7.038223765639312e+29M

Annual income

$703,199,891,284,667,200,000,000,000,000,000,000.00/yr

Blended yield

99.91%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

PAVMZ

No analyst data

Altman Z

-10.4

Piotroski

4/9

ORCC

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$16.00

+18.7% upside vs current

Range: $16.00 — $16.00

Altman Z

0.5

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PAVMZ buys

ORCC buys

Politician	Chamber	Ticker	Type	Amount	Date
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-06-23
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$250,001 - $500,000	2022-06-16
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-06-14
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$50,001 - $100,000	2022-06-13
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$50,001 - $100,000	2022-06-10
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-06-09
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-06-08
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$50,001 - $100,000	2022-06-03
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-05-24
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$100,001 - $250,000	2022-05-20

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricPAVMZORCC

Forward yield	222222.22% ✓	9.79%
Annual dividend / share	$2.00 ✓	$1.32
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0% ✓	-50%
Portfolio after 10y	$1.4076447531278624e+30M	$21.4K ✓
Annual income after 10y	$1,406,399,782,569,334,400,000,000,000,000,000,000.00 ✓	$1.04
Total dividends collected	$1.4075632434891558e+30M ✓	$1.0K
Payment frequency	quarterly	quarterly
Sector	Stock	BDC

Year-by-year: PAVMZ vs ORCC ($10,000, DRIP)

Year	PAVMZ Portfolio	PAVMZ Income/yr	ORCC Portfolio	ORCC Income/yr	Gap
1← crossover	$22,232,922	$22,222,222.22	$11,190	$489.61	+$22.22M → PAVMZ
2	$46,198,082,523	$46,174,293,296.41	$12,229	$256.01	+$46198.07M → PAVMZ
3	$89,718,752,943,223	$89,669,320,994,923.30	$13,216	$130.74	+$89718752.93M → PAVMZ
4	$162,845,393,609,755,680	$162,749,394,544,106,430.00	$14,207	$66.02	+$162845393609.74M → PAVMZ
5	$276,249,735,879,778,500,000	$276,075,491,308,616,120,000.00	$15,234	$33.17	+$276249735879778.50M → PAVMZ
6	$437,989,462,258,048,500,000,000	$437,693,875,040,657,100,000,000.00	$16,317	$16.62	+$437989462258048512.00M → PAVMZ
7	$649,026,142,700,674,900,000,000,000	$648,557,493,976,058,700,000,000,000.00	$17,468	$8.32	+$649026142700674875392.00M → PAVMZ
8	$898,874,153,179,794,200,000,000,000,000	$898,179,695,207,104,400,000,000,000,000.00	$18,695	$4.16	+$8.988741531797941e+23M → PAVMZ
9	$1,163,523,886,474,633,300,000,000,000,000,000	$1,162,562,091,130,731,000,000,000,000,000,000.00	$20,006	$2.08	+$1.1635238864746333e+27M → PAVMZ
10	$1,407,644,753,127,862,300,000,000,000,000,000,000	$1,406,399,782,569,334,400,000,000,000,000,000,000.00	$21,407	$1.04	+$1.4076447531278624e+30M → PAVMZ

PAVMZ vs ORCC: Complete Analysis 2026

PAVMZ — Stock

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Full PAVMZ Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →

📬

Get this PAVMZ vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PAVMZ vs SCHD PAVMZ vs JEPI PAVMZ vs O PAVMZ vs KO PAVMZ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.